OR WAIT null SECS
In this episode of Drug Digest, Chris Spivey, editorial director, and Meg Rivers, senior editor, dive into APIs, excipients, and formulation advances, specifically pairing the right APIs and excipients for optimizing formulations.
In this Drug Digest episode, Chris Spivey, editorial director, and Meg Rivers, senior editor, dive into APIs, excipients, and formulation advances, specifically pairing the right APIs and excipients for optimizing formulations.
Nitin Swarnakar, manager NA applications lab (pharma solutions), BASF, is a formulation scientist with more than 14 years of combined (academic research/training/industrial) experience and a strong track record of publications primarily focused on various formulation aspects of small, peptide, and protein molecules for oral and parenteral applications.
Gregory Lane, PhD, senior principal investigator, Bristol Myers Squibb, started working at Bristol-Myers Squibb (BMS) company in the year 2000 as a PhD organic chemist in the small-molecule API process technology department. During that time, he developed scalable syntheses and utilized process analytical technology (PAT) to monitor reactions and crystallizations from the laboratory to the pilot plant.
Matthias Bucerius, Head of Actives and Formulation, MilliporeSigma, the Life Science Business of Merck KGaA, Darmstadt, Germany, serves as head of actives and formulation at MilliporeSigma, the US and Canadian life science business of Merck KGaA, Darmstadt, Germany. He joined the company in 2004 after working as a strategy consultant.
Anil Kane, PhD, Global Head of Technical and Scientific Affairs, Pharma Services, Thermo Fisher Scientific, has more than 25 years of experience in the science and business of taking molecules through the entire drug development process, spanning early-stage development to scale-up and commercial manufacturing and includes technical transfers between global sites and drug life cycle management.
Stephen Hoag, professor and director of the APhL, Dept. of Pharmaceutical Sciences, University of Maryland School of Pharmacy, oversees project management, provides scientific oversight of projects, and handles client relations. In addition to his academic experience, he has worked for the World Health Organization, 3M Pharmaceuticals, and Abbott Laboratories.
Ilan Avni, VP BD, marketing, and IP, Wavelength Pharmaceuticals, has more than 20 years of experience in the global pharma, API, and medical devices industries. Avni has been with Wavelength Pharmaceuticals since 2006 and served in various business development, pipeline, and portfolio management roles.
This episode of Drug Digest is sponsored by:
Drug Digest is a tech talk video series with the Pharmaceutical Technology editors, who interview industry experts to discuss the emerging opportunities, obstacles, and advances in the pharmaceutical and biopharmaceutical industry for the research, development, formulation, analysis, upstream and downstream processing, manufacturing, supply chain, and packaging of drug products.